Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk)

地西他滨/四氢尿苷 (EpiDestiny/Novo Nordisk)

Report date: 2026/04/13 20:02:18

Base Information

Drug NameDecitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk)
Drug Alias NameEclipseNDecTetrahydrouridine/DecitabineEPI-01NN 7533
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionCytidine deaminase inhibitorsDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsCytidine deaminaseDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsCytopeniaMyelodysplastic SyndromesAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Africa +[12] 
CombinationsYes DecitabineTetrahydrouridine
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEpicdestiny
China Registration ClassN/A

Develop Information

Active CompaniesTreebough Therapies LlcEpidestiny IncNovo Nordisk A/S
Inactive CompaniesUniversity Of Illinois At Chicago
Active IndicationsCytopeniaMyelodysplastic SyndromesAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A